Author:
Le Xiuning,Nadler Eric,Costa Daniel B.,Heymach John Victor
Funder
Boehringer Ingelheim Pharmaceuticals, Inc
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference40 articles.
1. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–7.
2. Evans M, O’Sullivan B, Smith M, Hughes F, Mullis T, Trim N, et al. Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases. Pathol Oncol Res. 2019;25(4):1401–9.
3. Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302–16.
4. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530.
5. US FDA. EXKIVITY™ (mobocertinib) capsules, for oral use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Accessed 2 Nov 2022.